Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2012-01-24 M&A Activity
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
FORM F-4
M&A Activity Classification · 95% confidence The document is a Form F-4 registration statement filed with the SEC, which is used for registering securities in connection with business combinations such as mergers. The text references a reincorporation merger proposal, proxy statement/prospectus, and meetings of stockholders and warrant holders to vote on the merger. It includes detailed information about the merger structure, voting instructions, and securities to be registered. This type of filing is related to merger and acquisition activity, specifically the registration and solicitation materials for a merger transaction. It is not an annual report, earnings release, or other financial report. The presence of a proxy statement/prospectus and merger details aligns with the M&A Activity category rather than the Merger & Acquisition (MA) category, which is reserved for merger communications like Form 425 or tender offer filings. Therefore, the appropriate classification is M&A Activity (TAR). The document length and content confirm it is the actual filing, not just an announcement or certification.
2012-01-24 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a filing by BioCancell Ltd. pursuant to Rule 425 under the Securities Act of 1933, which is a disclosure related to a corporate restructuring involving a reverse merger. It references a Current Report on Form 8-K issued by BioCancell Therapeutics Inc. and discusses the upcoming filing of a registration statement on Form F-4 that will include a proxy statement and prospectus related to the restructuring. The document is primarily an announcement and disclosure about the proposed transaction and the forthcoming filings, not the filings themselves or detailed financial reports. It does not contain financial statements or detailed financial analysis but rather informs about the restructuring process and regulatory filings to come. Therefore, it fits best under the category of Merger & Acquisition (MA) filings, which include merger communications and related disclosures such as Form 425 filings.
2011-11-07 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.